Downregulation of miR‑505 promotes cell proliferation, migration and invasion, and predicts poor prognosis in breast cancer

Wang,Jian; Liu,Haibo; Li,Minghong

doi:10.3892/ol.2019.10334

Downregulation of miR‑505 promotes cell proliferation, migration and invasion, and predicts poor prognosis in breast cancer

Authors:
- Jian Wang
- Haibo Liu
- Minghong Li
View Affiliations

Affiliations: Department of Laboratory Medicine, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China
Published online on: May 7, 2019 https://doi.org/10.3892/ol.2019.10334
Pages: 247-254

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs are involved in the tumor progression of various cancer types. The present study aimed to determine the prognostic significance of microRNA‑505 (miR‑505) in patients with breast cancer and investigate the functional role of miR‑505 in BCa progression. The expression of miR‑505 was estimated using reverse transcription‑quantitative polymerase chain reaction. Kaplan‑Meier survival curves and Cox regression analysis were used to evaluate the prognostic value of miR‑505 in patients with BCa. Cell experiments were performed to assess the biological function of miR‑505 during BCa progression. A significant downregulated expression level of miR‑505 was observed in BCa tissues and cells compared with the corresponding controls (P<0.001). The expression of miR‑505 was significantly associated with distant metastasis status (P=0.013) and Tumor‑Node‑Metastasis staging (P=0.002). Furthermore, the overall survival time was significantly shorter for patients with low miR‑505 expression compared with those with high miR‑505 expression (P<0.001). In addition, miR‑505 was identified as an independent prognostic factor for BCa. The results of cell experiments revealed that an overexpression of miR‑505 could significantly inhibit BCa cell proliferation, migration and invasion, whereas a downregulation of miR‑505 significantly enhanced BCa cell proliferation, migration and invasion (P<0.05). In summary, all data indicated that a low miR‑505 expression level is associated with a poor prognosis for patients with BCa and promotes tumor cell proliferation, migration and invasion. Therefore, the aberrant expression of miR‑505 may serve as a therapeutic target for BCa.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Globalcancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360. 2005. View Article : Google Scholar : PubMed/NCBI
3	Bombonati A and Sgroi DC: The molecular pathology of breast cancer progression. J Pathol. 223:307–317. 2011. View Article : Google Scholar : PubMed/NCBI
4	Reis-Filho JS and Lakhani SR: The diagnosis and management of pre-invasive breast disease: Genetic alterations in pre-invasive lesions. Breast Cancer Res. 5:313–319. 2003. View Article : Google Scholar : PubMed/NCBI
5	Dai K, Qin F, Zhang H, Liu X, Guo C, Zhang M, Gu F, Fu L and Ma Y: Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy. Oncotarget. 7:4770–4784. 2016.PubMed/NCBI
6	Schmitz KH, DiSipio T, Gordon LG and Hayes SC: Adverse breast cancer treatment effects: The economic case for making rehabilitative programs standard of care. Support Care Cancer. 23:1807–1817. 2015. View Article : Google Scholar : PubMed/NCBI
7	Turchinovich A, Weiz L and Burwinkel B: Extracellular miRNAs: The mystery of their origin and function. Trends Biochem Sci. 37:460–465. 2012. View Article : Google Scholar : PubMed/NCBI
8	Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, Bertrand E and Filipowicz W: Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 309:1573–1576. 2005. View Article : Google Scholar : PubMed/NCBI
9	Xiang J, Wu Y, Li DS, Wang ZY, Shen Q, Sun TQ, Guan Q and Wang YJ: MiR-584 suppresses invasion and cell migration of thyroid carcinoma by regulating the target oncogene ROCK1. Oncol Res Treat. 38:436–440. 2015. View Article : Google Scholar : PubMed/NCBI
10	Lu Y, Hu J, Sun W, Li S, Deng S and Li M: MiR-29c inhibits cell growth, invasion, and migration of pancreatic cancer by targeting ITGB1. Onco Targets Ther. 9:99–109. 2016.PubMed/NCBI
11	Bai J, Zhang Z, Li X and Liu H: MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression. Cancer Biomark. 15:599–608. 2015. View Article : Google Scholar : PubMed/NCBI
12	Zhou C, Lu Y and Li X: MiR-339-3p inhibits proliferation and metastasis of colorectal cancer. Oncol Lett. 10:2842–2848. 2015. View Article : Google Scholar : PubMed/NCBI
13	Dan B, Luo J, Li K and Chen S: Prognostic value of miR-375 for survival outcomes in various cancers: A systematic review and meta-analysis. Oncol Res Treat. 41:47–50. 2018. View Article : Google Scholar : PubMed/NCBI
14	Lin F, Yao L, Xiao J, Liu D and Ni Z: MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma. Onco Targets Ther. 7:1583–1591. 2014.PubMed/NCBI
15	Zheng K, Liu W, Liu Y, Jiang C and Qian Q: MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1. Oncol Lett. 9:869–874. 2015. View Article : Google Scholar : PubMed/NCBI
16	Yang H, Yu J, Wang L, Ding D, Zhang L, Chu C, Chen Q, Xu Z, Zou Q and Liu X: miR-320a is an independent prognostic biomarker for invasive breast cancer. Oncol Lett. 8:1043–1050. 2014. View Article : Google Scholar : PubMed/NCBI
17	Deng Y and Chen Y: Increased expression of miR-29a and its prognostic significance in patients with cholangiocarcinoma. Oncol Res Treat. 40:128–132. 2017. View Article : Google Scholar : PubMed/NCBI
18	Liu YJ, Li W, Chang F, Liu JN, Lin JX and Chen DX: MicroRNA-505 is downregulated in human osteosarcoma and regulates cell proliferation, migration and invasion. Oncol Rep. 39:491–500. 2018.PubMed/NCBI
19	Ma C, Xu B, Husaiyin S, Wang L, Wusainahong K, Ma J, Zhu K and Niyazi M: MicroRNA-505 predicts prognosis and acts as tumor inhibitor in cervical carcinoma with inverse association with FZD4. Biomed Pharmacother. 92:586–594. 2017. View Article : Google Scholar : PubMed/NCBI
20	Lu L, Qiu C, Li D, Bai G, Liang J and Yang Q: MicroRNA-505 suppresses proliferation and invasion in hepatoma cells by directly targeting high-mobility group box 1. Life Sci. 157:12–18. 2016. View Article : Google Scholar : PubMed/NCBI
21	Chen S, Sun KX, Liu BL, Zong ZH and Zhao Y: MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-alpha. Mol Cancer. 15:112016. View Article : Google Scholar : PubMed/NCBI
22	Matamala N, Vargas MT, Gonzalez-Campora R, Minambres R, Arias JI, Menendez P, Andres-Leon E, Gomez-Lopez G, Yanowsky K, Calvete-Candenas J, et al: Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 61:1098–1106. 2015. View Article : Google Scholar : PubMed/NCBI
23	Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et al: Staging system for breast cancer: Revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 83:803–819. 2003. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Akram M, Iqbal M, Daniyal M and Khan AU: Awareness and current knowledge of breast cancer. Biol Res. 50:332017. View Article : Google Scholar : PubMed/NCBI
26	Shi M and Guo N: MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev. 35:328–334. 2009. View Article : Google Scholar : PubMed/NCBI
27	Blank PR, Schwenkglenks M, Moch H and Szucs TD: Human epidermal growth factor receptor 2 expression in early breast cancer patients: A swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res Treat. 124:497–507. 2010. View Article : Google Scholar : PubMed/NCBI
28	Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K and Sarkar S: Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 34:1071–1077. 2014.PubMed/NCBI
29	Lei F, Zhang L, Li X, Lin X, Wu S, Li F and Liu J: Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer. BMC Cancer. 14:4572014. View Article : Google Scholar : PubMed/NCBI
30	Xiong G, Deng L, Zhu J, Rychahou PG and Xu R: Prolyl-4-hydroxylase alpha subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer. 14:12014. View Article : Google Scholar : PubMed/NCBI
31	Zhu C, He L, Zhou X, Nie X and Gu Y: Sulfatase 2 promotes breast cancer progression through regulating some tumor-related factors. Oncol Rep. 35:1318–1328. 2016. View Article : Google Scholar : PubMed/NCBI
32	Dragomir M, Mafra ACP, Dias SMG, Vasilescu C and Calin GA: Using microRNA networks to understand cancer. Int J Mol Sci. 19:E18712018. View Article : Google Scholar : PubMed/NCBI
33	Huang LL, Huang LW, Wang L, Tong BD, Wei Q and Ding XS: Potential role of miR-139-5p in cancer diagnosis, prognosis and therapy. Oncol Lett. 14:1215–1222. 2017. View Article : Google Scholar : PubMed/NCBI
34	Long JP, Dong LF, Chen FF and Fan YF: miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells. Oncol Lett. 17:1573–1580. 2019.PubMed/NCBI
35	Sun EH, Zhou Q, Liu KS, Wei W, Wang CM, Liu XF, Lu C and Ma DY: Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. Eur Rev Med Pharmacol Sci. 18:2783–2788. 2014.PubMed/NCBI
36	Chai C, Wu H, Wang B, Eisenstat DD and Leng RP: MicroRNA-498 promotes proliferation and migration by targeting the tumor suppressor PTEN in breast cancer cells. Carcinogenesis. 39:1185–1196. 2018. View Article : Google Scholar : PubMed/NCBI
37	Gao S, Cao C, Dai Q, Chen J and Tu J: miR-202 acts as a potential tumor suppressor in breast cancer. Oncol Lett. 16:1155–1162. 2018.PubMed/NCBI
38	Lu X and Lu J: The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer. Clin Lab. 61:187–190. 2015. View Article : Google Scholar : PubMed/NCBI
39	Cong J, Liu R, Wang X, Wang J, Wang H and Hou J: Low miR-498 expression levels are associated with poor prognosis in ovarian cancer. Eur Rev Med Pharmacol Sci. 19:4762–4765. 2015.PubMed/NCBI
40	Li W, Jin X, Zhang Q, Zhang G, Deng X and Ma L: Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol. 7:3287–3292. 2014.PubMed/NCBI
41	Yu H, Li H, Qian H, Jiao X, Zhu X, Jiang X, Dai G and Huang J: Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer. Med Oncol. 31:2832014. View Article : Google Scholar : PubMed/NCBI